William A Werbel1, Christine M Durand2,3. 1. Department of Medicine, Johns Hopkins University School of Medicine, 725 North Wolfe Street/PCTB Room 228, Baltimore, MD, 21205, USA. 2. Department of Medicine, Johns Hopkins University School of Medicine, 725 North Wolfe Street/PCTB Room 228, Baltimore, MD, 21205, USA. christinedurand@jhmi.edu. 3. Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. christinedurand@jhmi.edu.
Abstract
PURPOSE OF REVIEW: End-stage organ disease prevalence is increasing among HIV-infected (HIV+) individuals. Trial and registry data confirm that solid organ transplantation (SOT) is efficacious in this population. Optimizing access to transplant and decreasing complications represent active frontiers. RECENT FINDINGS: HIV+ recipients historically experienced 2-4-fold higher rejection. Integrase strand transferase inhibitors (INSTIs) minimize drug interactions and may reduce rejection along with lymphodepleting induction immunosuppression. Hepatitis C virus (HCV) coinfection has been associated with inferior outcomes, yet direct-acting antivirals (DAAs) may mitigate this. Experience in South Africa and the US HIV Organ Policy Equity (HOPE) Act support HIV+ donor to HIV+ recipient (HIV D+/R+) transplantation. SOT is the optimal treatment for end-stage organ disease in HIV+ individuals. Recent advances include use of INSTIs and DAAs in transplant recipients; however, strategies to improve access to transplant are needed. HIV D+/R+ transplantation is under investigation and may improve access and provide insights for HIV cure and pathogenesis research.
PURPOSE OF REVIEW: End-stage organ disease prevalence is increasing among HIV-infected (HIV+) individuals. Trial and registry data confirm that solid organ transplantation (SOT) is efficacious in this population. Optimizing access to transplant and decreasing complications represent active frontiers. RECENT FINDINGS: HIV+ recipients historically experienced 2-4-fold higher rejection. Integrase strand transferase inhibitors (INSTIs) minimize drug interactions and may reduce rejection along with lymphodepleting induction immunosuppression. Hepatitis C virus (HCV) coinfection has been associated with inferior outcomes, yet direct-acting antivirals (DAAs) may mitigate this. Experience in South Africa and the US HIV Organ Policy Equity (HOPE) Act support HIV+ donor to HIV+ recipient (HIV D+/R+) transplantation. SOT is the optimal treatment for end-stage organ disease in HIV+ individuals. Recent advances include use of INSTIs and DAAs in transplant recipients; however, strategies to improve access to transplant are needed. HIV D+/R+ transplantation is under investigation and may improve access and provide insights for HIV cure and pathogenesis research.
Authors: E Righi; A Londero; F Pea; S Bonora; P Nasta; P Della Siega; P Delle Foglie; G Villa; O Giglio; S Dal Zoppo; U Baccarani; M Bassetti Journal: Transpl Infect Dis Date: 2015-01-12 Impact factor: 2.228
Authors: Ran Reshef; Selina M Luger; Elizabeth O Hexner; Alison W Loren; Noelle V Frey; Sunita D Nasta; Steven C Goldstein; Edward A Stadtmauer; Jacqueline Smith; Sarah Bailey; Rosemarie Mick; Daniel F Heitjan; Stephen G Emerson; James A Hoxie; Robert H Vonderheide; David L Porter Journal: N Engl J Med Date: 2012-07-12 Impact factor: 91.245
Authors: E Teicher; F Boufassa; D Vittecoq; T M Antonini; M-G Tateo; A Coilly; A-M Roque-Afonso; N Kassis-Chikhani; O Lambotte; P Ichai; D Samuel; J-C Duclos-Vallee Journal: Transpl Infect Dis Date: 2015-09-26 Impact factor: 2.228
Authors: Norah A Terrault; Michelle E Roland; Thomas Schiano; Lorna Dove; Michael T Wong; Fred Poordad; Margaret V Ragni; Burc Barin; David Simon; Kim M Olthoff; Lynt Johnson; Valentina Stosor; Dushyantha Jayaweera; John Fung; Kenneth E Sherman; Aruna Subramanian; J Michael Millis; Douglas Slakey; Carl L Berg; Laurie Carlson; Linda Ferrell; Donald M Stablein; Jonah Odim; Lawrence Fox; Peter G Stock Journal: Liver Transpl Date: 2012-06 Impact factor: 5.799
Authors: Marwan M Azar; Maricar F Malinis; J Moss; Richard N Formica; Merceditas S Villanueva Journal: Int J STD AIDS Date: 2016-07-10 Impact factor: 1.359
Authors: Georges Ambaraghassi; Héloïse Cardinal; Daniel Corsilli; Claude Fortin; Marie-Chantal Fortin; Valérie Martel-Laferrière; Jacques Malaise; Michel R Pâquet; Danielle Rouleau Journal: Can J Kidney Health Dis Date: 2017-03-02
Authors: William A Werbel; Sunjae Bae; Sile Yu; Fawaz Al Ammary; Dorry L Segev; Christine M Durand Journal: Am J Transplant Date: 2020-08-13 Impact factor: 8.086